Wealth Tribune

Sunday, October 6, 2024
Sunday, October 6, 2024
All Right Reserved. Designed and Developed by PenciDesign
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Home Headlines Consumer health giant Haleon sees higher revenue in 2024

Consumer health giant Haleon sees higher revenue in 2024

by Uma Rajagopal
0 comments
2024 02 29T070858Z 1 LYNXNPEK1S06R RTROPTP 4 HALEON RESULTS scaled

Consumer health giant Haleon sees higher revenue in 2024

(Reuters) – Sensodyne toothpaste-maker Haleon said on Thursday it expected higher revenue in 2024, thanks to firm demand for its household products ranging from painkillers, nasal sprays and multivitamins.

Haleon said its organic revenue would rise between 4%-6% this year, as the consumer healthcare company reported its first full-year results since it was spun off from GSK in 2022.

Analysts on average expect organic revenue to grow by 4.5%, according to a company-compiled consensus.

 

(Reporting by Eva Mathews in Bengaluru; Editing by Subhranshu Sahu)

 

Recent Post

Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.